MARKETS / PKTX
PHARMACEUTICAL PREPARATIONS · SMALL CAP
ProtoKinetix, Inc. PKTX
19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-393,650
Growth
—
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2014 · Revenue 0.0 · Net income -0.2
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -123.0%
Each USD of equity lost 123 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Operating income $B | · | · | · | · | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 0.00 | 0.00 | −0.01 | −0.01 | 0.00 | −0.03 | −0.02 | 0.00 | −0.01 | −0.01 | −0.01 | 0.00 | 0.00 | 0.00 | −0.01 | −0.02 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −123.0 | −93.6 | −96.9 | −492.6 | −599.4 | −1552.8 | −1041.2 | −392.6 | −347.8 | −338.4 | · | · | · | · | · | · | · | · | · |
| Shares out B | 0.41 | 0.37 | 0.35 | 0.32 | 0.30 | 0.29 | 0.28 | 0.26 | 0.25 | 0.24 | 0.22 | 0.18 | 0.14 | 0.13 | 0.12 | 0.08 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 54 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 22 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007